Lobeline-induced learning improvement of rats in the radial-arm maze

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 1, 2003, Pages 133-139

  Levin, Edward D ^a   Christopher, Channelle N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Learning; Lobeline; Radial arm maze; Repeated acquisition

Indexed keywords

LOBELINE; NICOTINE TARTRATE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; GENERAL CONDITION IMPROVEMENT; INJECTION; LEARNING; MAZE TEST; MENTAL PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT; WORKING MEMORY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LOBELINE; MAZE LEARNING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1642390218     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00216-8     Document Type: Article

References (55)

1. Arendash G.W., Sanberg P.R., Sengstock G.J. Nicotine enhances the learning and memory of aged rats. Pharmacol. Biochem. Behav. 52:1995;517-523.
2. Arendash G.W., Sengstock G.J., Sanberg P.R., Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:1995;252-259.
3. Brioni J.D., Arneric S.P. Nicotinic receptor agonists facilitate retention of avoidance training: participation of dopaminergic mechanisms. Behav. Neural Biol. 59:1993;57-62.
4. Brioni J.D., O'Neill A.B., Kim D.J., Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 238:1993;1-8.
5. Curzon P., Kim D.J.B., Decker M.W. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol. Biochem. Behav. 49:1994;877-882.
6. Damaj M.I., Patrick G.S., Creasy K.R., Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282:1997;410-419.
7. Decker M.W., Majchrzak M.J., Arneric S.P. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45:1993;571-576.
8. Decker M.W., Buckley M.J., Brioni J.D. Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and locomotor activity in mice. Drug Dev. Res. 31:1994;52-58.
9. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics - minireview. Life Sci. 56:1995;545-570.
10. Driscoll P. Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats. Psychopharmacologia. 46:1976;119-121.
11. Driscoll P., Battig K. The effect of small doses of mecamylamine on shuttlebox behavior in the guinea-pig. Experientia. 29:1973;991-993.
12. Dunnett S.B., Martel F.L. Proactive interference effects on short-term memory in rats: 1. Basic parameters and drug effects. Behav. Neurosci. 104:1990;655-665.
13. Dwoskin L.P., Crooks P.A. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J. Pharmacol. Exp. Ther. 298:2001;395-402.
14. Dwoskin L.P., Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63:2002;89-98.
15. Erickson C.K. Studies on the mechanism of avoidance facilitation by nicotine. Psychopharmacologia. 22:1971;257-268.
16. Essman W.B., Essman S.G. Cholinergic mechanisms and avoidance behavior acquisition: effects of nicotine in mice. Psychol. Rep. 29:1971;987-993.
17. Evangelista A.M., Gattoni R.C., Izquierdo I. Effect of amphetamine, nicotine and hexamethonium on performance of a conditioned response during acquisition and retention trials. Pharmacology. 3:1970;91-96.
18. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288:1999;88-92.
19. Fujii S., Ji Z., Sumikawa K. Inactivation of alpha7 ACh receptors and activation of non-alpha7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region. Neurosci. Lett. 286:2000;134-138.
20. Garg M. The effect of nicotine on two different types of learning. Psychopharmacologia. 15:1969;408-414.
21. Gilliam D.M., Schlesinger K. Nicotine-produced relearning deficit in C57Bl/6J and DBA/2J mice. Psychopharmacology. 86:1985;291-295.
22. 3dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59:1992;848-856.
23. Haroutunian V., Barnes E., Davis K.L. Cholinergic modulation of memory in rats. Psychopharmacology. 87:1985;266-271.
24. Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E., Bardo M.T. Lobeline attenuates D-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 298:2001;172-179.
25. 3H]5-HT from rat hippocampal slices. Neuropharmacology. 35:1996;1769-1777.
26. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-431.
27. Levin E.D., Rezvani A.H. Development of nicotinic drug therapy for cognitive disorders. Eur. J. Pharmacol. 393:2000;141-146.
28. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology. 138:1998;217-230.
29. Levin E.D., Toll K., Chang G., Christopher N.C., Briggs S.J. Epibatidine, a potent nicotinic agonist: effects on learning and memory in the radial-arm maze. Med. Chem. Res. 6:1996;543-554.
30. Levin E.D., Bettegowda C., Blosser J., Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. 10:1999;675-680.
31. Miller D.K., Crooks P.A., Dwoskin L.P. Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology. 39:2000;2654-2662.
32. Miller D.K., Crooks P.A., Teng L., Witkin J.M., Munzar P., Goldberg S.R.et al. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296:2001;1023-1034.
33. Newhouse P.A., Kelton M. Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm. Acta Helv. 74:2000;91-101.
34. Newhouse P.A., Potter A., Corwin J., Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 10:1994;93-107.
35. Newhouse P., Potter A., Kelton M., Corwin J. Nicotinic treatment of Alzheimer's disease. Biol. Psychiatry. 49:2001;268-278.
36. 3H)nicotine binding sites in the rat brain. Drug Alcohol Depend. 16:1985;9-17.
37. Oliverio A. Effects of mecamylamine on avoidance conditioning and maze learning of mice. J. Pharmacol. Exp. Ther. 154:1966;350-356.
38. Oliverio A. Effects of nicotine and strychnine on transfer of avoidance learning in the mouse. Life Sci. 7:1968;1163-1167.
39. Papke R.L., Thinschmidt J.S., Moulton B.A., Meyer E.M., Poirier A. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br. J. Pharmacol. 120:1997;429-438.
40. Peele D.B., Baron S.P. Effects of scopolamine on repeated acquisition on radial-arm maze performance by rats. J. Exp. Anal. Behav. 49:1988;275-290.
41. Rao T.S., Correa L.D., Lloyd G.K. Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA) evoked acetylcholine release in vitro: evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors. Neuropharmacology. 36:1997;39-50.
42. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 29:1990;619-624.
43. Rochford J., Sen A.P., Quirion R. Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J. Pharmacol. Exp. Ther. 277:1996;1267-1275.
44. Sansone M., Castellano C., Battaglia M., Ammassari-Teule M. Effects of oxiracetam-nicotine combinations on active and passive avoidance learning in mice. Pharmacol. Biochem. Behav. 39:1991;197-200.
45. Sasaki H., Yanai M., Meguro K., Sekizawa K., Ikarashi Y., Maruyama Y.et al. Nicotine improves cognitive disturbance in rodents fed with a choline-deficient diet. Pharmacol. Biochem. Behav. 38:1991;921-925.
46. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Hardman J.G., Limbird L.E., Gilman A.G. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. 2001;193-213 McGraw-Hill, New York.
47. 3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280:1997;1432-1444.
48. 3H]dihydrotetrabenazine binding and releases [v]dopamine from rat striatal synaptic vesicles: comparison with D-amphetamine. J. Neurochem. 71:1998;258-265.
49. Terry A.V., Buccafusco J.J., Jackson W.J., Zagrodnik S., Evans-Martin F.F., Decker M.W. Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology. 123:1996;172-181.
50. Terry A.V., Williamson R., Gattu M., Beach J.W., McCurdy C.R., Sparks J.A.et al. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology. 37:1998;93-102.
51. Terry A.V., Buccafusco J.J., Prendergast M.A. Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Drug Dev. Res. 47:1999;127-136.
52. Turchi J., Holley L.A., Sarter M. Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology. 118:1995;195-205.
53. Warburton D.M., Wesnes K., Shergold K., James M. Facilitation of learning and state dependency with nicotine. Psychopharmacology. 89:1986;55-59.
54. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., McFalls E. et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 51:1995;509-514.
55. Woodruff-Pak D.S., Li Y.T., Kem W.R. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645:1994;309-317.